Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Follicular 19Lymphoma 19Lymphoma, Mantle-Cell 17Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Lymphoma, Non-Hodgkin 9Recurrence 6Hodgkin Disease 6Waldenstrom Macroglobulinemia 5Neoplasms 3Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Sezary Syndrome 1Proteostasis Deficiencies 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × Bendamustine Hydrochloride × 1 year × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡